Recruiting

Testing a new medication for Kaposi sarcoma skin cancer

Plain-English translation of NCT04305691 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called ixazomib to see if it can help treat Kaposi sarcoma, a cancer that causes abnormal growths on the skin. The study will measure how well the medication works, how safe it is, and how it affects the virus that causes this cancer. Researchers will also track changes in quality of life for people taking this treatment.

Kaposi sarcoma is a serious condition, especially for people with compromised immune systems. Current treatment options may not work well for everyone, so doctors are looking for new medications to improve outcomes and give patients more effective choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with Kaposi sarcoma that affects the skin and can be measured by doctors
you have at least five visible skin lesions from the cancer, or lesions covering a total area of at least 700 square millimeters
you know your HIV status (whether you are HIV-positive or HIV-negative, with recent documentation)
you are able to understand the study and willing to sign an informed consent form
you are well enough to participate, with a life expectancy of more than 3 months
you have acceptable blood test results (normal or near-normal counts of white blood cells, red blood cells, and platelets, and normal liver function)

You likely don't qualify if…

you are unwilling or unable to understand and consent to the study
you have severe liver problems or very low blood cell counts that don't meet the study's minimum requirements
you received a platelet transfusion within 3 days before enrollment to artificially boost your numbers
you have a life expectancy of 3 months or less

What participation looks like

You will take the medication by mouth on days 1, 8, and 15 of each 28-day cycle, for up to 12 cycles (about 9 months). If your cancer improves significantly, you may continue for another 12 cycles. Throughout the study, you will have regular blood tests and doctor visits to check how you're responding and monitor for side effects. After finishing treatment, you'll be followed up for 4 weeks and then periodically for up to 2 years.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(11 sites)

United States

UC San Diego, San Diego, California

Zuckerberg San Francisco General Hospital, San Francisco, California

University of Miami Miller School of Medicine, Miami, Florida

University of Illinois Cancer Center, Chicago, Illinois

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland